Stem Cell Therapy Market Growing at 18.2% CAGR During (2022-2028) to Reach USD 6.2 Billion | The Insight Partners

The Insight Partners published latest research report on "Stem Cell Therapy Market Size Report, Revenue, Trends, Segments, Share & Forecasts to 2028 - COVID-19 Impact and Global Analysis By Type, Treatment, Application, End User and Geography”, the global market is expected to grow from USD 2,278.49 million in 2022 to USD 6,206.89 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2022 to 2028.


Request Sample PDF Brochure:


Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryos, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.

The COVID-19 pandemic had a positive impact on the stem cell therapy market. The application of stem cells in the treatment of COVID-19 infection has gathered the attention of medical researchers, resulting in a higher number of clinical trials. Regenerative medicine based on cellular therapies may be developed as a treatment option for patients, lowering infection rates and mortality. Research institutes and companies are collaborating to develop novel treatment options for COVID-19. For instance, in April 2020, Infectious Disease Research Institute and Celularity announced that the US FDA had approved a clinical trial application to develop cell-based therapy for COVID-19. Thus, researchers are increasingly attempting to develop stem cell therapies targeting COVID-19. In January 2020, researchers from the University of Miami administered two stem cell infusions to COVID-19 patients suffering from lung damage. The results concluded that there were no significant side effects, and the therapy was reliable. Thus, increasing demand for regenerative medicines has had a positive effect on the stem cell therapy market during the COVID-19 pandemic. 


Directly Purchase Premium Copy of Stem Cell Therapy Market Growth Report (2022-2028) at:


Global Stem Cell Therapy Market Share Report, Segmentations, Regional & Country Scope:


Report Coverage


Market Size Value in

USD 2,278.49 million in 2022

Market Size Value by

USD 6,206.89 million by 2028

Growth rate

CAGR of 18.2% from 2022 to 2028

Forecast Period


Base Year


No. of Pages


No. of Tables


No. of Charts & Figures


Historical data available


Segments covered

Type, Treatment, Application, and End User

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Companies Covered

MEDIPOST, Pharmicell Co., Inc., RichSource, BioTime, Inc., Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., Caladrius Biosciences, Inc., TiGenix NV, AlloSource

Key Research Capabilities

Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies, SWOT Analysis, New Product Development



Browse key market insights spread across 206 pages with 138 list of tables & 81 list of figures from the report, "Stem Cell Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, and Other Stem Cell Therapy), Treatment (Allogeneic and Autologous), Application (Musculoskeletal, Dermatology, Cardiology, Drug Discovery & Development, and Other Applications), and End User (Hospitals & Specialty Clinics and Academic & Research Institutes), and Geography" in detail along with the table of contents:


Leading companies operating in the global stem cell therapy market have undertaken various organic and inorganic growth strategies. The global stem cell therapy market comprises MEDIPOST, Pharmicell Co., Inc; RichSource      , BioTime, Inc.; Mesoblast Limited, Holostem Terapie Avanzate Srl; U.S. Stem Cell, Inc; Caladrius Biosciences, Inc.; TiGenix NV, AlloSource. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as product launches in the global stem cell therapy market, resulting in the market's growth. Moreover, the market players have also deployed several inorganic strategies, including mergers & acquisitions and collaborations that helped the Company to strengthen its revenue, which allows the Company to hold a strong position in the market.


Growth Strategies Undertaken by the Players operating in the Global Stem Cell Therapy Market:

Oct-2022: Medipost (CEO Won-Il Oh) announced its new GMP facilities will house ten cleanrooms and production facilities equipped with up-to-date equipment exclusively for Contract Development and Manufacturing Organization (CDMO), marking the launch of its CDMO business for cell and gene therapy products in Korea.

Sep-2022: Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs.

June-2021: Allogene Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The FDA granted Fast Track designation based on the potential of ALLO-605 to address the unmet need for patients who have failed other standard multiple myeloma therapies.

May-2021: Spacelabs Healthcare a division of OSI Systems, Inc. launched Lifescreen Pro event screening system to diagnose cardiac arrhythmias accurately and economically. Lifescreen Pro expands the Company’s non-invasive cardiology offerings.



Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Stem Cell Manufacturing Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Stem Cell Banking Market Forecast to 2028 - Covid-19 Impact and Global Analysis

Synthetic Stem Cells Market Forecast to 2028 - Covid-19 Impact and Global Analysis

Vaccine, Indulin, and Stem Cell Market Forecast to 2028 - COVID-19 Impact and Global Analysis

Cell Expansion Market to 2027 - Global Analysis and Forecasts




About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.


Contact Us:

If you have any queries about this report or if you would like further information, please contact us:


Contact Person: Sameer Joshi


Phone: +1-646-491-9876

Press Release:

Back to news